Gilead Sciences (GILD) received a major pipeline setback with disappointing results from a phase III trial of darusentan in which it failed to achieve its primary endpoint. The drug was being studied under an international clinical trial (DAR-312) for the treatment of resistant hypertension. As a result of the setback, Gilead is considering the option [...] (GILD) Gilead Sciences Suffers Stage III Setback